NRx Pharmaceuticals, Inc.

NasdaqCM:NRXP Stock Report

Market Cap: US$32.4m

NRx Pharmaceuticals Management

Management criteria checks 3/4

NRx Pharmaceuticals' CEO is Jonathan Javitt, appointed in Mar 2022, has a tenure of 2.83 years. total yearly compensation is $630.20K, comprised of 95.6% salary and 4.4% bonuses, including company stock and options. directly owns 12.58% of the company’s shares, worth $4.08M. The average tenure of the management team and the board of directors is 2.8 years and 1.1 years respectively.

Key information

Jonathan Javitt

Chief executive officer

US$630.2k

Total compensation

CEO salary percentage95.6%
CEO tenure2.8yrs
CEO ownership12.6%
Management average tenure2.8yrs
Board average tenure1.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jonathan Javitt's remuneration changed compared to NRx Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$20m

Jun 30 2024n/an/a

-US$25m

Mar 31 2024n/an/a

-US$26m

Dec 31 2023US$630kUS$603k

-US$30m

Sep 30 2023n/an/a

-US$36m

Jun 30 2023n/an/a

-US$39m

Mar 31 2023n/an/a

-US$37m

Dec 31 2022US$874kUS$867k

-US$40m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$88m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$377kUS$275k

-US$93m

Sep 30 2021n/an/a

-US$108m

Jun 30 2021n/an/a

-US$76m

Mar 31 2021n/an/a

-US$76m

Dec 31 2020US$615kUS$275k

-US$52m

Compensation vs Market: Jonathan's total compensation ($USD630.20K) is about average for companies of similar size in the US market ($USD642.68K).

Compensation vs Earnings: Jonathan's compensation has been consistent with company performance over the past year.

CEO

Jonathan Javitt (67 yo)

2.8yrs

Tenure

US$630,198

Compensation

Dr. Jonathan C. Javitt, M.D., M.P.H. is the Interim Chief Executive Officer of NRx Pharmaceuticals, Inc. since October 11, 2024 and is it's Chief Scientist Officer since March 9, 2022. He is a Co-Founder o...

Leadership Team

NamePositionTenureCompensationOwnership
Jonathan Javitt
Co-Founder2.8yrsUS$630.20k12.58%
$ 4.1m
Richard Narido
Treasurerno dataUS$298.02k0%
$ 0
Michael Abrams
Chief Financial Officerno datano datano data
Riccardo Panicucci
Chief Manufacturing & Technology Officer4yrsUS$240.00kno data
Suzanne Messere
Investor Relationsno datano datano data
Philip Lavin
Chief Methodologistno datano datano data
Matthew Duffy
Chief Business Officer & Co-CEO of Hope Therapeutics1.8yrsno datano data

2.8yrs

Average Tenure

62yo

Average Age

Experienced Management: NRXP's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jonathan Javitt
Co-Founder1.1yrsUS$630.20k12.58%
$ 4.1m
Chaim Hurvitz
Independent Director3.7yrsUS$52.50k1.84%
$ 595.8k
Patrick Flynn
Independent Director3.7yrsUS$67.50k0.49%
$ 158.8k
Janet Rehnquist
Independent Director1.1yrsno datano data
Dennis McBride
Independent Directorless than a yearno datano data

1.1yrs

Average Tenure

67yo

Average Age

Experienced Board: NRXP's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 10:32
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NRx Pharmaceuticals, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Jason KolbertD. Boral Capital LLC.
Vernon BernardinoH.C. Wainwright & Co.